Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-24 @ 3:35 PM
NCT ID:
NCT04733092
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of primary inflammatory knee osteoarthritis of the target joint defined by a knee osteoarthritis according to the American College of Rheumatology (ACR) classification and a score ≥ 2 according to the classification of Kellgren and Lawrence
* Patient not eligible for surgery (or refusing surgery)
* Analog Visual Scale (VAS) pain ≥ 40 mm despite analgesic treatment for at least 3 months
* Failure or intolerance of treatment with NSAIDs and/or tramadol and/or acetaminophen, and/or failure or intolerance or patient refusing strong opioids medication (morphine, codeine)
* Failure or patient refusal of corticosteroid infiltration
* Patient who has signed an informed consent
Exclusion Criteria:
* Patient who is unable or unable to comply with the follow-up schedule
* Infiltration of target joint less than three months old
* Treated hyperthyroidism
* Traumatic injury, hemorrhage or bleeding less than 1 week old in the target joint
* Known arterial disease of the lower limbs stage ≥ 2 according to the classification of Leriche and Fontaine
* Known severe allergy to Lipiodol® and/or iodized contrast product
* Known severe kidney failure (creatinine clearance \< 30 ml/min)
* Pregnant or breastfeeding woman
* Patient not affiliated with a French Medicare
* Patient benefiting from legal protection
* Participation in another interventional research
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
35 Years
Maximum Age:
90 Years
Study:
NCT04733092
Study Brief:
Protocol Section:
NCT04733092